NASDAQ: SPTXSeaport Therapeutics Inc Stock
$17.97+0.53 (+3.04%)
Updated Jun 16, 2026
SPTX Price
$17.97
Fair Value Price
N/A
Market Cap
$961.94M
52 Week Low
$14.85
52 Week High
$23.00
P/E
N/A
P/B
-8.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.16
Operating Cash Flow
N/A
Beta
1.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SPTX Overview
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPTX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SPTX
Ranked#154 of 462
Ranked#154 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important SPTX news, forecast changes, insider trades & much more!
SPTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPTX's short-term assets ($188.34M) exceed its short-term liabilities ($14.22M)
Short-term Liabilities Financials
SPTX's short-term assets ($188.34M) exceed its long-term liabilities ($3.74M)
Long-term Liabilities Financials
SPTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more SPTX due diligence checks available for Premium users.
Valuation
SPTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.32x
Industry
4.86x
SPTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$25.4M
Profit Margin
0%
Assets to liabilities
Assets
$227.7M
Liabilities
$18.0M
Debt to equity
-0.16
SPTX's short-term assets ($188.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPTX's short-term assets ($188.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SPTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.2M
Investing
$27.9M
Financing
-$783.0k
SPTX vs Biotech Stocks
Seaport Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.